Do peptides help with inflammatory bowel disease (Crohn disease and ulcerative colitis)?
2 peptides are graded for inflammatory bowel disease (Crohn disease and ulcerative colitis) on this page. The strongest grade is animal-only evidence, for KPV and BPC-157. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for inflammatory bowel disease (Crohn disease and ulcerative colitis)?
Specialist care: mesalamine for mild to moderate ulcerative colitis; corticosteroids for flares only; thiopurines or methotrexate for maintenance; biologics (anti-TNF, anti-integrin, anti-IL-12/23, anti-IL-23) and JAK or S1P modulators for moderate to severe disease; surgery for refractory or complicated disease.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for inflammatory bowel disease (Crohn disease and ulcerative colitis)?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| KPV | Evidence: Animal-only evidence | Reduced colitis severity and inflammatory cytokines in mouse models, including when given orally; no human study; PCAC recommended it for the 503A bulks list in July 2026. [1] [2] |
| BPC-157 | Evidence: Animal-only evidence | Healed colitis, fistula, and other gut lesion models in rats; no published human IBD trial. [3] [4] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Are there peptides for gut health?
Not for inflammatory bowel disease. KPV and BPC-157, the peptides most marketed for gut health, reduced colitis and healed gut lesions only in rodent models, and neither has a published human trial. FDA's compounding advisory committee recommended KPV for the 503A bulks list in July 2026, which is not an approval. The one peptide drug approved for a common gut condition is linaclotide (Linzess), for irritable bowel syndrome with constipation. [1] [3] [5] [7]
Is any peptide FDA approved for inflammatory bowel disease (Crohn disease and ulcerative colitis)?
No. None of the peptides graded for inflammatory bowel disease (Crohn disease and ulcerative colitis) is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [6]
Has any peptide been tested in a randomized trial for inflammatory bowel disease (Crohn disease and ulcerative colitis)?
No. The best evidence for any peptide graded for inflammatory bowel disease (Crohn disease and ulcerative colitis) is animal only evidence, so none has been shown to work in a randomized human trial for this use. [1] [2] [3] [4]
From the blog
- BPC-157 for gut health: the animal evidence and the missing human trials
BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
- Oral BPC-157: what capsules and pills were tested for, and what is missing
Oral BPC-157 worked in rat gut, ligament, and fistula studies. No study has measured how much an oral capsule absorbs in people, and the two registered oral studies have posted no results.
Sources
- [1]Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseasePubMed 18092346, 2008
- [2]PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationPubMed 18061177, 2008
- [3]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
- [4]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implicationsPubMed 27138887, 2016
- [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [6]Drugs@FDA: FDA-approved drugs databaseFDA
- [7]FDA prescribing information for Linzess (linaclotide) capsules, via DailyMedFDA, 2023